REGENXBIO, Inc. (RGNX)
8.06
-2.66
(-24.81%)
USD |
NASDAQ |
Aug 24, 16:00
8.08
+0.02
(+0.25%)
After-Hours: 20:00
REGENXBIO Enterprise Value : 725.36M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 725.36M |
| August 20, 2026 | 743.77M |
| August 19, 2026 | 795.77M |
| August 18, 2026 | 744.32M |
| August 17, 2026 | 758.40M |
| August 14, 2026 | 727.80M |
| August 13, 2026 | 722.11M |
| August 12, 2026 | 735.65M |
| August 11, 2026 | 721.57M |
| August 10, 2026 | 709.11M |
| August 07, 2026 | 725.36M |
| August 06, 2026 | 755.69M |
| August 05, 2026 | 713.44M |
| August 04, 2026 | 702.61M |
| August 03, 2026 | 684.19M |
| July 31, 2026 | 669.57M |
| July 30, 2026 | 692.86M |
| July 29, 2026 | 665.78M |
| July 28, 2026 | 664.69M |
| July 27, 2026 | 670.65M |
| July 24, 2026 | 671.74M |
| July 23, 2026 | 699.90M |
| July 22, 2026 | 697.19M |
| July 21, 2026 | 704.78M |
| July 20, 2026 | 703.69M |
| Date | Value |
|---|---|
| July 17, 2026 | 680.40M |
| July 16, 2026 | 751.36M |
| July 15, 2026 | 809.31M |
| July 14, 2026 | 810.40M |
| July 13, 2026 | 835.31M |
| July 10, 2026 | 900.31M |
| July 09, 2026 | 992.39M |
| July 08, 2026 | 969.64M |
| July 07, 2026 | 958.26M |
| July 06, 2026 | 947.97M |
| July 02, 2026 | 864.02M |
| July 01, 2026 | 853.73M |
| June 30, 2026 | 793.60M |
| June 29, 2026 | 708.53M |
| June 26, 2026 | 638.85M |
| June 25, 2026 | 626.46M |
| June 24, 2026 | 612.53M |
| June 23, 2026 | 611.49M |
| June 22, 2026 | 566.07M |
| June 18, 2026 | 500.52M |
| June 17, 2026 | 505.68M |
| June 16, 2026 | 455.61M |
| June 15, 2026 | 462.84M |
| June 12, 2026 | 441.67M |
| June 11, 2026 | 422.06M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 532.50B |
| Capricor Therapeutics, Inc. | 218.62M |
| Biogen, Inc. | 39.09B |
| Ardelyx, Inc. | 943.54M |
| Ocugen, Inc. | 459.21M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 22.71M |
| Revenue (Quarterly) | 108.02M |
| Total Expenses (Quarterly) | 85.31M |
| EPS Diluted (Quarterly) | 0.4283 |
| Gross Profit Margin (Quarterly) | 95.56% |
| Profit Margin (Quarterly) | 21.02% |
| Earnings Yield | -46.96% |
| Normalized Earnings Yield | -46.96 |